We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
-7.13%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$216M
AUM Growth
-$131M
Cap. Flow
-$83.5M
Cap. Flow %
-38.69%
Top 10 Hldgs %
42.5%
Holding
85
New
16
Increased
22
Reduced
28
Closed
19

Top Buys

Rank Stock Value
1
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$4.88M
2
SAGE
Sage Therapeutics
SAGE
+$4.34M
3
TECX
Tectonic Therapeutic
TECX
+$4.04M
4
SDGR icon
Schrodinger
SDGR
+$3.02M
5
ITMR
Itamar Medical Ltd. American Depository Shares
ITMR
+$2.98M

Top Sells

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$14.2M
2
BSX icon
Boston Scientific
BSX
+$12.4M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$9.42M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$8.04M
5
TFX icon
Teleflex
TFX
+$7M

Sector Composition

Rank Sector Weight
1 Healthcare 92.89%
2 Technology 1.17%
3 Industrials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PVLA
51
Palvella Therapeutics
PVLA
$2.23B
$1.14M 0.53%
6,236
-1,533
-20% -$386K
YARW
52
Yarrow Bioscience, Inc. Common Stock
YARW
$114M
$1.09M 0.5%
+113
New +$1.77M
APRE icon
53
Aprea Therapeutics
APRE
$8.46M
$1.04M 0.48%
+1,502
New +$1.1M
GYRE icon
54
Gyre Therapeutics
GYRE
$706M
$941K 0.44%
+28,698
New +$1.32M
MNKD icon
55
MannKind Corp
MNKD
$1.24B
$928K 0.43%
901,117
-524,185
-37% -$708K
HALO icon
56
Halozyme
HALO
$11.6B
$908K 0.42%
50,466
-114,534
-69% -$2.17M
GNMK
57
DELISTED
GenMark Diagnostics, Inc
GNMK
$824K 0.38%
200,000
-220,000
-52% -$1.03M
MBIO icon
58
Mustang Bio
MBIO
$4.59M
$813K 0.38%
405
+2
+0.5% +$5.13K
RCM
59
DELISTED
R1 RCM Inc. Common Stock
RCM
$786K 0.36%
86,492
-119,228
-58% -$1.43M
RETA
60
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$726K 0.34%
5,027
-10,973
-69% -$2.12M
ATXS
61
DELISTED
Astria Therapeutics
ATXS
$645K 0.3%
+25,912
New +$803K
IMVT icon
62
Immunovant
IMVT
$8.8B
$625K 0.29%
+40,125
New +$604K
LAB icon
63
Standard BioTools
LAB
$312M
$572K 0.27%
225,391
-174,609
-44% -$574K
AMRN
64
Amarin Corp
AMRN
$297M
$304K 0.14%
3,806
-2,978
-44% -$989K
APYX icon
65
Apyx Medical
APYX
$126M
$127K 0.06%
35,497
+102
+0.3% +$685
CLPT icon
66
ClearPoint Neuro
CLPT
$463M
$90K 0.04%
+25,078
New +$123K
ASND icon
67
Ascendis Pharma A/S
ASND
$16.8B
– –
-23,004
Closed -$3.2M
BLFS icon
68
BioLife Solutions
BLFS
$1.71B
– –
-166,000
Closed -$2.69M
BSX icon
69
Boston Scientific
BSX
$74.5B
– –
-275,000
Closed -$12.4M
GH icon
70
Guardant Health
GH
$22.2B
– –
-30,250
Closed -$2.36M
KIDS icon
71
OrthoPediatrics
KIDS
$649M
– –
-60,000
Closed -$2.82M
RGNX icon
72
Regenxbio
RGNX
$720M
– –
-85,000
Closed -$3.48M
TELA icon
73
TELA Bio
TELA
$32.3M
– –
-25,000
Closed -$324K
TFX icon
74
Teleflex
TFX
$6.03B
– –
-18,600
Closed -$7M
TNDM icon
75
Tandem Diabetes Care
TNDM
$1.63B
– –
-134,959
Closed -$8.04M
1 2
3
4

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q1 2020 Portfolio in Review

As of Q1 2020, Parkman Healthcare Partners held 85 positions worth $216M, down 38% from $346M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Parkman Healthcare Partners withdrew a net $83.5M in Q1 2020, closing 19 positions and reducing 28 holdings. Its most notable exit was Zimmer Biomet, an estimated $14.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Technology and Industrials.

Against the trend, Parkman Healthcare Partners opened a new position in Momenta Pharmaceuticals, Inc. worth $4.77M.

  • Parkman Healthcare Partners's largest Q1 2020 buy was Momenta Pharmaceuticals, Inc.: 175,453 shares worth $4.77M.
  • Parkman Healthcare Partners added most to Tectonic Therapeutic in Q1 2020, an estimated $4.04M increase.
  • Parkman Healthcare Partners's biggest Q1 2020 reduction was Seagen Inc. Common Stock, cutting an estimated $9.42M.
  • Parkman Healthcare Partners fully exited Zimmer Biomet in Q1 2020, selling an estimated $14.2M.
  • Parkman Healthcare Partners's ten largest holdings make up 42% of its $216M portfolio in Q1 2020.
  • Parkman Healthcare Partners opened 16 new positions and closed 19 in Q1 2020.
  • Parkman Healthcare Partners's portfolio value fell 38% quarter-over-quarter to $216M.

Based on Parkman Healthcare Partners's 13F filing for Q1 2020, filed 15 May 2020.